SavedAdd your journal

Journals / Journal of Health Sciences and Medicine / 2022 / Cilt: 5 - Sayı: 6

The findings about relationship between autoimmune thyroid disease and first-trimester aneuploidy results

Naziye GÜRKAN
Halime ÇALI ÖZTÜRK
Pages
1661–1665
Publication Date
2022-10-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: There is no statistically significant relationship between thyroid autoimmune diseases and the first-trimester aneuploidy results.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of this study was to investigate the relationship between thyroid autoantibody and first-trimester aneuploidy results.
📊
Key Findings & Data:Material and Method: This retrospective case-control study was conducted between December 2019 and May 2022.
💡
Conclusion & Impact:Conclusion: There is no statistically significant relationship between thyroid autoimmune diseases and the first-trimester aneuploidy results.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Aneuploidy · thyroid · autoimmune thyroid disease

Abstract

Aim: The aim of this study was to investigate the relationship between thyroid autoantibody and first-trimester aneuploidy results. Thyroid autoimmunity (TAI) is the most common autoimmune disorder. Patients with TAI are usually euthyroid. Thyroid peroxidase (TPO-Ab) in patients with or without thyroid dysfunction is associated with infertility, recurrent embryo implantation failure, and early pregnancy loss. The impact of TPO-Ab on first-trimester aneuploidy test results needs to be studied. Material and Method: This retrospective case-control study was conducted between December 2019 and May 2022. Patients with thyroid autoantibody positivity (n=112) were included in the study as the case group. The control group was selected from age and body mass index (BMI)-matched patients (n=130). Nuchal translucency (NT), crown rump length (CRL), pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (β-hCG)) values were compared between the two groups. Results: This study included two hundred forty two age-matched (29.86±4.51) and BMI-matched (23.96±2.34) women. There was no statistically significant difference between groups in terms of free thyroxine (FT4), PAPP-A and free β-hCG (p>0.05). NT as a marker for major chromosomal defects and CRL were comparable in case and control groups (p>0.05). Conclusion: There is no statistically significant relationship between thyroid autoimmune diseases and the first-trimester aneuploidy results.

🔖

Cite This Article

GÜRKAN, N., ÖZTÜRK, H. Ç. (2022). The findings about relationship between autoimmune thyroid disease and first-trimester aneuploidy results. Journal of Health Sciences and Medicine, Cilt: 5 - Sayı: 6, 1661–1665. https://ajindex.com/articles/776418

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Mc Sweeney LC, Monteith C, Kelliher N, et al. 252: Changing patterns of invasive fetal diagnostic testing in the era of NIPT. AJOG 2018; 218: 162-3.
  2. Mikwar M, MacFarlane AJ, Marchetti F. Mechanisms of oocyte aneuploidy associated with advanced maternal age. Mutat Res Rev Mutat Res 2020; 785: 108320. Bouariu A, Panaitescu AM, Nicolaides KH. First trimester prediction of adverse pregnancy outcomes-identifying pregnancies at risk from as early as 11-13 weeks. Medicina (Kaunas) 2022; 58: 332. LeFevre NM, Sundermeyer RL. Fetal aneuploidy: screening and diagnostic testing. Am Fam Physician 2020; 101: 481-8.
  3. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013; 15: 395-8. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics; Committee on Genetics; Society for Maternal-Fetal Medicine. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. Obstet Gynecol 2020; 136: 48-69.
  4. Shahat ARS, Greco G. The economic costs of childhood disability: a literature review. Int J Environ Res Public Health 2021; 18: 3531. Karadeniz RS, Altay M, Karasu Y, Gelişen O, Haberal A. Comparison of triple and qadrupple test in second trimester Down syndrome screening. GORM 2009; 15: 4-7.
  5. Kagan KO, Sonek J, Kozlowski P. Antenatal screening for chromosomal abnormalities. Arch Gynecol Obstet 2022; 305: 825-35.
  6. Canick JA, Kellner LH. First trimester screening for aneuploidy: serum biochemical markers. Semin Perinatol 1999; 23: 359-68.
  7. Dhillon-Smith RK, Coomarasamy A. TPO antibody positivity and adverse pregnancy outcomes. Best Pract Res Clin Endocrinol Metab 2020; 34: 101433. Saravanan P, Dayan CM. Thyroid autoantibodies. Endocrinol Metab Clin North Am 2001; 30: 315-7. Chardès T, Chapal N, Bresson D, et al. The human anti-thyroid peroxidase autoantibody repertoire in Graves' and Hashimoto's autoimmune thyroid diseases. Immunogenetics 2002; 54: 141-57.
  8. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41: 1149-60.
  9. Xie J, Jiang L, Sadhukhan A, et al. Effect of antithyroid antibodies on women with recurrent miscarriage: A meta-analysis. Am J Reprod Immunol 2020; 83: e13238. Midan MF, Elfayoumy KN, El-Bassiony WM, Al-Metwally AA. Thyroid-stimulating hormone in pregnancy: are we in need of a lower cutoff value? BMFJ 2018; 35: 241. Iravani AT, Saeedi MM, Pak